Table 2 Distribution of mutations of the UroSEEK gene panel in invasive bladder cancer
pT1 tumors | Muscle-invasive bladder cancer | p-value | |||
|---|---|---|---|---|---|
UroSEEK genes | 101/111 (91%) | 40/43 (93%) | 0.933 | ||
TERTSeqS | 80/111 (72%) | 27/43 (63%) | 0.354 | ||
UroSeqS | 62/111 (56%) | 32/43 (74%) | 0.053 | ||
FGFR3 | 21/111 (19%) | 5/43 (12%) | 0.399 | ||
TP53 | 31/111 (28%) | 23/43 (54%) | 0.005 | ||
PIK3CA | 10/111 (9%) | 1/43 (2%) | 0.273 | ||
CDKN2A | 5/111 (5%) | 7/43 (16%) | 0.035 | ||
HRAS | 3/111 (3%) | 1/43 (2%) | 1.0 | ||
KRAS | 3/111 (3%) | 0/43 (0%) | 0.661 | ||
ERBB2 | 3/111 (3%) | 1/43 (2%) | 1.0 | ||
VHL | 4/111 (4%) | 0/43 (0%) | 0.486 | ||
MLL | 0/111 (0%) | 0/43 (0%) | . | ||
MET | 0/111 (0%) | 0/43 (0%) | . | ||
